Trastuzumab Rezetecan Extends PFS in HER2-Low Advanced Breast Cancer in Phase 3 HORIZON-Breast06
Start here
Hengrui Medicine's trastuzumab rezetecan (SHR-A1811, also reported under the name ruzaltatug) met its endpoint in the phase 3 HORIZON-Breast06 study, extending progression-free survival in patients with HER2-low advanced breast cancer who had not previously received chemotherapy. Median PFS was 16.6 months with the drug versus 6.8 months in the chemotherapy arm. The results position SHR-A1811 alongside existing HER2-directed antibody-drug conjugates in the HER2-low setting. Full details beyond the topline PFS figures, including overall survival data, safety profile, regulatory filings and publication of the complete dataset, have not yet been reported.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickHORIZON-Breast06 Phase 3: Trastuzumab Rezetecan Extends PFS in HER2-Low Advanced Breast Cancer
The phase 3 HORIZON-Breast06 study of Hengrui Medicine's trastuzumab rezetecan (SHR-A1811) extended progression-free survival in patients with HER2-low advanced breast cancer.
- mp.weixin.qq.comPickHengrui Reports Phase 3 HORIZON-Breast06: Ruzaltatug Median PFS 16.6 Months in Chemo-Naive HER2-Low Advanced Breast Cancer
Hengrui Pharma reported Phase 3 HORIZON-Breast06 results for ruzaltatug (SHR-A1811) in HER2-low advanced breast cancer. In chemotherapy-naive patients, median PFS was 16.6 months with ruzaltatug versus 6.8 months in the chemotherapy arm.
Heat trend for this story
Not enough continuous observation yet to draw a trend.